Key Points
- Encompass Health EVP Patrick William Tuer sold 682 shares on May 11 at an average price of $104.56, for total proceeds of about $71,310. After the sale, he still owned 24,755 shares valued at roughly $2.59 million.
- The company beat quarterly earnings and revenue expectations, reporting EPS of $1.60 versus the $1.51 estimate and revenue of $1.59 billion, up 9% year over year. Encompass Health also raised its FY 2026 EPS guidance to $5.89-$6.11.
- Analysts remain constructive on EHC overall, with a consensus “Buy” rating and average target price of $144.17, even though Barclays recently trimmed its price target to $140.00.
Encompass Health Corporation (NYSE:EHC - Get Free Report) EVP Patrick William Tuer sold 682 shares of the company's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the transaction, the executive vice president owned 24,755 shares of the company's stock, valued at $2,588,382.80. This represents a 2.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Encompass Health Stock Up 3.2%
EHC opened at $108.15 on Wednesday. The stock has a market capitalization of $10.73 billion, a P/E ratio of 18.06, a P/E/G ratio of 2.28 and a beta of 0.72. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The business has a 50 day simple moving average of $103.02 and a 200-day simple moving average of $106.67. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17.
Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm earned $1.37 EPS. The company's revenue for the quarter was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, equities analysts anticipate that Encompass Health Corporation will post 5.97 earnings per share for the current fiscal year.
Encompass Health Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health's dividend payout ratio is currently 12.69%.
Institutional Investors Weigh In On Encompass Health
A number of institutional investors and hedge funds have recently bought and sold shares of EHC. First Horizon Corp acquired a new position in shares of Encompass Health in the third quarter worth about $34,000. WPG Advisers LLC grew its stake in shares of Encompass Health by 73.3% in the 4th quarter. WPG Advisers LLC now owns 324 shares of the company's stock valued at $34,000 after buying an additional 137 shares in the last quarter. Westside Investment Management Inc. increased its stake in shares of Encompass Health by 56.7% during the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company's stock worth $35,000 after purchasing an additional 101 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in Encompass Health during the fourth quarter worth $37,000. Finally, Assetmark Inc. increased its holdings in shares of Encompass Health by 88.1% during the 3rd quarter. Assetmark Inc. now owns 299 shares of the company's stock valued at $38,000 after acquiring an additional 140 shares during the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. Barclays lowered their target price on Encompass Health from $153.00 to $140.00 and set an "overweight" rating for the company in a research note on Tuesday, May 5th. Wall Street Zen upgraded Encompass Health from a "hold" rating to a "buy" rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $144.17.
Read Our Latest Stock Report on EHC
About Encompass Health
(
Get Free Report)
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
